Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: A phase II study

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 1, 2003, Pages 21-26

  Kim, Jeri ^a   Millikan, Randall E ^a   Smith, Terry L ^a   Tu, Shi Ming ^a   Pagliaro, Lance C ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Immunotherapy; Interleukin 2; Urothelial carcinoma

Indexed keywords

AMINOTRANSFERASE; CISPLATIN; CREATININE; INTERLEUKIN 2; NAPROXEN; PARACETAMOL; PETHIDINE; BIOLOGICAL RESPONSE MODIFIER;

ACIDEMIA; ADULT; AGED; ANEMIA; CANCER SURVIVAL; CARCINOMA; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; GRANULOCYTOPENIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; INTESTINE PERFORATION; MALE; METASTASIS; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROTHELIAL CARCINOMA; UROTHELIUM; ARTICLE; BONE TUMOR; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PATHOLOGY; SALVAGE THERAPY; SURVIVAL; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; URINARY TRACT CANCER;

ADULT; AGED; BIOLOGICAL RESPONSE MODIFIERS; BONE NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FEVER; HUMANS; HYPOTENSION; INTERLEUKIN-2; MALE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT FAILURE; UROLOGIC NEOPLASMS;

EID: 0141922741     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00207-7     Document Type: Conference Paper

References (42)

1. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
2. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564-9.
3. Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response. Br J Urol 1995;76:321-4.
4. Seidman AD, Scher HI, Gabrilove JL. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993; 11:408-14.
5. Loehrer PJ, Elson P, Dreicer R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma. Eastern Cooperative Oncology Group Trial. J Clin Oncol 1994;12:483-8.
6. Logothetis CJ, Finn LD, Smith T, et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 1995;13:2272-7.
7. Vaughn DJ. Review and outlook for the role of paclitaxel in urothelial carcinoma. Semin Oncol 1999;26(Suppl):117-22.
8. Sternberg CN. Gemcitabine in bladder cancer. Semin Oncol 2000; 27(Suppl):31-9.
9. Roth BJ. Ifosfamide in the treatment of bladder cancer. Semin Oncol 1996;23(Suppl):50-5.
10. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 17:3068-77.
11. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 1995;154: 1719-22.
12. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 1976;193: 1007-8.
13. Grimm EA, Rosenberg SA. Production and properties of human IL-2. In: Fathman CG, Fitch FW, editors. Isolation, Characterization and Utilization of T Lymphocyte Clones. New York: Academic Press, 1982.
14. Wang BS, Heacock EH, Zheng CS, Tilney NL, Mannick JA. Restoration of allogeneic responsiveness of lymphocytes from cyclosporin A-treated animals with interleukin-2. Transplantation 1982;33:454-6.
15. Thomas ML, Weigle WO. Cell-mediated immunity in aged mice: an underlying lesion in IL-2 synthesis. J Immunol 1982;128:2358-61.
16. Cheever MA, Greenberg PD, Fefer A, Gillis S. Augmentation of the anti-tumor therapeutic efficacy of long term cultured T lymphocytes by in vivo administration of purified interleukin-2. J Exp Med 1982; 155:968-80.
17. Ruscetti FW, Gallo RC. Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood 1981;57:379-94.
18. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant interleukin-2 produced in E. coli. Science 1984;223: 1412-4.
19. Lotze MT, Franan LW, Sharrow SO, Robb RJ, Rosenberg SA. In vivo administration of purified human interleukin-2. I. Half life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 1985;134:157-66.
20. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985;135:2865-75.
21. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:879-97.
22. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
23. Sosman JA, Kohler PC, Hank J, et al. Repetitive weekly cycles of recombinant interleukin-2: responses of renal cell carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60-3.
24. Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Int Med 1987;108:518-23.
25. Paciucci PA, Holland JF, Glidewell O, Odchimar R. Recombinant interleukin-2 (rIL-2) by continuous infusion and adoptive transfer of rIL-2 activated cells in patients with advanced cancer. J Clin Oncol 1989;7:869-78.
26. Paciucci PA, Bhadrdwaj S, Odchimar R, et al. Immunotherapy for metastatic cancer with recombinant interleukin-2 by continuous infusion with and without adoptive cell transfer. Proc ASCO 1988;7: 630 [abstract].
27. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961;13:346-53.
28. Tomita Y, Matsumoto Y, Nishiyama T, Fujiwara M. Reduction of major histocompatibility complex class I antigens on invasive and high-grade transitional cell carcinoma. J Pathol 1990;162:157-64.
29. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-8.
30. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTSs. Nature 1998; 392:86-9.
31. Witte RS, Manola J, Burch PA, et al. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drug 1998;16:191-5.
32. Otto T, Bex A, Krege S, Walz PH, Rubben H. Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (MI). Cancer 1997;80:465-70.
33. Schwartzentruber D, Lotze MT, Rosenberg SA. Colonic perforation: an unusual complication of therapy with high-dose interleukin-2. Cancer 1988;62:2350-3.
34. Atzpodien J, Kirchner H. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 1990;68:1-11.
35. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193: 1007-8.
36. Rosenberg SA. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180-99.
37. Minami Y, Kono T, Myazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993;11:245-67.
38. Caliguiri MA, Zmuidzinas A, Manley TJ, et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509-26.
39. Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol 1993;20(Suppl):3-10.
40. Stein RC, Malkovska V, Morgan S, et al. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br J Cancer 1991;63:275-8.
41. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori 1993;79:397-400.
42. Meropol NJ, Porter M, Blumenson LE, et al. Daily subcutaneous injection of low-dose interleukin-2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 1996;2:669-77.